Review



sino biological catalog  (Sino Biological)


Bioz Verified Symbol Sino Biological is a verified supplier
Bioz Manufacturer Symbol Sino Biological manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94

    Structured Review

    Sino Biological sino biological catalog
    ( A ) Diversity of influenza A HA. Phylogenetic tree of IAV HAs (left). Timeline of <t>influenza</t> <t>H1N1</t> and H3N2 circulation; symbols represent strains used in this study (middle). Pairwise identity of HAs from viruses used in this study mapped onto structures of HA [Protein Data Bank (PDB) 3LZG and 4FNK] (right). ( B ) Neutralization potencies determined by microneutralization for down-selected antibodies against a panel of IAVs. Strains are indicated as in (A). H1N1 strains: A/WSN/1933, A/USSR/90/1977, A/Memphis/4/1987, A/Massachusetts/1/1990, A/Beijing/262/1995, A/New Caledonia/20/1999, A/Solomon Islands/3/2006, A/New York/08-1326/2008, A/California/07/2009, A/Michigan/45/2015, and A/Sydney/5/2021. H3N2 strains: A/Aichi/2/1968, A/Bilthoven/1761/1976, A/Beijing/353/1989, A/Johannesburg/33/1994, A/Brisbane/8/1996, A/Fujian/411/2002, A/Wisconsin/67/2005, A/Perth/16/2009, A/Switzerland/9715293/2013, and A/Kansas/14/2017. Neutralization assays were performed in technical duplicate. N.N., non-neutralizing. ( C ) ELISA binding reactivity at 10 or 1 μg/ml to A/Swine/Henan/SN13/2018 or A/Canine/Hainan/79/2019 (left) and BLI-based antibody competition with the indicated antibodies (right).
    Sino Biological Catalog, supplied by Sino Biological, used in various techniques. Bioz Stars score: 94/100, based on 3 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/sino biological catalog/product/Sino Biological
    Average 94 stars, based on 3 article reviews
    sino biological catalog - by Bioz Stars, 2026-02
    94/100 stars

    Images

    1) Product Images from "Conserved sites on the influenza H1 and H3 hemagglutinin recognized by human antibodies"

    Article Title: Conserved sites on the influenza H1 and H3 hemagglutinin recognized by human antibodies

    Journal: Science Advances

    doi: 10.1126/sciadv.adu9140

    ( A ) Diversity of influenza A HA. Phylogenetic tree of IAV HAs (left). Timeline of influenza H1N1 and H3N2 circulation; symbols represent strains used in this study (middle). Pairwise identity of HAs from viruses used in this study mapped onto structures of HA [Protein Data Bank (PDB) 3LZG and 4FNK] (right). ( B ) Neutralization potencies determined by microneutralization for down-selected antibodies against a panel of IAVs. Strains are indicated as in (A). H1N1 strains: A/WSN/1933, A/USSR/90/1977, A/Memphis/4/1987, A/Massachusetts/1/1990, A/Beijing/262/1995, A/New Caledonia/20/1999, A/Solomon Islands/3/2006, A/New York/08-1326/2008, A/California/07/2009, A/Michigan/45/2015, and A/Sydney/5/2021. H3N2 strains: A/Aichi/2/1968, A/Bilthoven/1761/1976, A/Beijing/353/1989, A/Johannesburg/33/1994, A/Brisbane/8/1996, A/Fujian/411/2002, A/Wisconsin/67/2005, A/Perth/16/2009, A/Switzerland/9715293/2013, and A/Kansas/14/2017. Neutralization assays were performed in technical duplicate. N.N., non-neutralizing. ( C ) ELISA binding reactivity at 10 or 1 μg/ml to A/Swine/Henan/SN13/2018 or A/Canine/Hainan/79/2019 (left) and BLI-based antibody competition with the indicated antibodies (right).
    Figure Legend Snippet: ( A ) Diversity of influenza A HA. Phylogenetic tree of IAV HAs (left). Timeline of influenza H1N1 and H3N2 circulation; symbols represent strains used in this study (middle). Pairwise identity of HAs from viruses used in this study mapped onto structures of HA [Protein Data Bank (PDB) 3LZG and 4FNK] (right). ( B ) Neutralization potencies determined by microneutralization for down-selected antibodies against a panel of IAVs. Strains are indicated as in (A). H1N1 strains: A/WSN/1933, A/USSR/90/1977, A/Memphis/4/1987, A/Massachusetts/1/1990, A/Beijing/262/1995, A/New Caledonia/20/1999, A/Solomon Islands/3/2006, A/New York/08-1326/2008, A/California/07/2009, A/Michigan/45/2015, and A/Sydney/5/2021. H3N2 strains: A/Aichi/2/1968, A/Bilthoven/1761/1976, A/Beijing/353/1989, A/Johannesburg/33/1994, A/Brisbane/8/1996, A/Fujian/411/2002, A/Wisconsin/67/2005, A/Perth/16/2009, A/Switzerland/9715293/2013, and A/Kansas/14/2017. Neutralization assays were performed in technical duplicate. N.N., non-neutralizing. ( C ) ELISA binding reactivity at 10 or 1 μg/ml to A/Swine/Henan/SN13/2018 or A/Canine/Hainan/79/2019 (left) and BLI-based antibody competition with the indicated antibodies (right).

    Techniques Used: Neutralization, Enzyme-linked Immunosorbent Assay, Binding Assay



    Similar Products

    94
    Sino Biological sino biological catalog
    ( A ) Diversity of influenza A HA. Phylogenetic tree of IAV HAs (left). Timeline of <t>influenza</t> <t>H1N1</t> and H3N2 circulation; symbols represent strains used in this study (middle). Pairwise identity of HAs from viruses used in this study mapped onto structures of HA [Protein Data Bank (PDB) 3LZG and 4FNK] (right). ( B ) Neutralization potencies determined by microneutralization for down-selected antibodies against a panel of IAVs. Strains are indicated as in (A). H1N1 strains: A/WSN/1933, A/USSR/90/1977, A/Memphis/4/1987, A/Massachusetts/1/1990, A/Beijing/262/1995, A/New Caledonia/20/1999, A/Solomon Islands/3/2006, A/New York/08-1326/2008, A/California/07/2009, A/Michigan/45/2015, and A/Sydney/5/2021. H3N2 strains: A/Aichi/2/1968, A/Bilthoven/1761/1976, A/Beijing/353/1989, A/Johannesburg/33/1994, A/Brisbane/8/1996, A/Fujian/411/2002, A/Wisconsin/67/2005, A/Perth/16/2009, A/Switzerland/9715293/2013, and A/Kansas/14/2017. Neutralization assays were performed in technical duplicate. N.N., non-neutralizing. ( C ) ELISA binding reactivity at 10 or 1 μg/ml to A/Swine/Henan/SN13/2018 or A/Canine/Hainan/79/2019 (left) and BLI-based antibody competition with the indicated antibodies (right).
    Sino Biological Catalog, supplied by Sino Biological, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/sino biological catalog/product/Sino Biological
    Average 94 stars, based on 1 article reviews
    sino biological catalog - by Bioz Stars, 2026-02
    94/100 stars
      Buy from Supplier

    94
    Sino Biological b cell probe
    ( A ) Diversity of influenza A HA. Phylogenetic tree of IAV HAs (left). Timeline of <t>influenza</t> <t>H1N1</t> and H3N2 circulation; symbols represent strains used in this study (middle). Pairwise identity of HAs from viruses used in this study mapped onto structures of HA [Protein Data Bank (PDB) 3LZG and 4FNK] (right). ( B ) Neutralization potencies determined by microneutralization for down-selected antibodies against a panel of IAVs. Strains are indicated as in (A). H1N1 strains: A/WSN/1933, A/USSR/90/1977, A/Memphis/4/1987, A/Massachusetts/1/1990, A/Beijing/262/1995, A/New Caledonia/20/1999, A/Solomon Islands/3/2006, A/New York/08-1326/2008, A/California/07/2009, A/Michigan/45/2015, and A/Sydney/5/2021. H3N2 strains: A/Aichi/2/1968, A/Bilthoven/1761/1976, A/Beijing/353/1989, A/Johannesburg/33/1994, A/Brisbane/8/1996, A/Fujian/411/2002, A/Wisconsin/67/2005, A/Perth/16/2009, A/Switzerland/9715293/2013, and A/Kansas/14/2017. Neutralization assays were performed in technical duplicate. N.N., non-neutralizing. ( C ) ELISA binding reactivity at 10 or 1 μg/ml to A/Swine/Henan/SN13/2018 or A/Canine/Hainan/79/2019 (left) and BLI-based antibody competition with the indicated antibodies (right).
    B Cell Probe, supplied by Sino Biological, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/b cell probe/product/Sino Biological
    Average 94 stars, based on 1 article reviews
    b cell probe - by Bioz Stars, 2026-02
    94/100 stars
      Buy from Supplier

    94
    Sino Biological recombinant influenza virus ca09 ha
    Initial immune characterization of HA DNA-LNP formulations and immunogenicity (A) Schematic of DNA-LNP N/P ratios and immunization regimen. (B–D) Biophysical characterization of DNA-LNPs at different N/P ratios. (B) Particle size; (C) polydispersity index (PDI); (D) zeta potential. (E) Representative fluorescence-activated cell sorting (FACS) plots of GC B cells. (F) Bar plots quantifying frequency of GC B cells. (G) Frequency of <t>CA09</t> HA-specific GC B cells. (H) Frequency of activated Tfh cells. (I) IFNγ ELISpot of splenocytes. (J) Representative TEM images of HA DNA-LNP (top) and HA mRNA-LNP (bottom). Scale bar 100 nm (K and L) Fold change cytokine induction in DLNs at 4 h (K) and 24 h (L) after immunization quantified using Luminex. (M and N) ELISpot assay measuring IFNα (M) and IFNγ (N) 20 h after stimulation of splenocytes ex vivo with DNA-LNP, plasmid DNA, or DNA-LNP in the presence of chemical inhibitors to the indicated DNA sensors. (O) Schematic of relevant pathways implicated in DNA-LNP sensing. Dots represent individual animals; n = 8–9 (E–H), n = 5 (I, K, and L), or n = 3–4 animals per group (L and M); data pooled or representative from two independent experiments (E–H, M, and N) or from one independent experiment (I–L). Plots show mean with SD (B–D and I) or geometric mean with geometric SD (F–H and K–N). Unpaired one-way ANOVA adjusted for multiple comparisons with Bonferroni corrections was used to compare groups (F–H, K, and L) or compared to DNA-LNP control (M and N). ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001.
    Recombinant Influenza Virus Ca09 Ha, supplied by Sino Biological, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/recombinant influenza virus ca09 ha/product/Sino Biological
    Average 94 stars, based on 1 article reviews
    recombinant influenza virus ca09 ha - by Bioz Stars, 2026-02
    94/100 stars
      Buy from Supplier

    94
    Sino Biological sino biological cat
    ( A ) Diversity of influenza A HA. Phylogenetic tree of influenza A virus HAs (left). Timeline of <t>influenza</t> <t>H1N1</t> and H3N2 circulation; symbols represent strains used in this study (middle). Pairwise identity of HAs from viruses used in this study mapped onto structures of HA (PDB: 3LZG and 4FNK) (right). ( B ) Neutralization potencies determined by microneutralization for down-selected antibodies against a panel of influenza A viruses. Strains are indicated as in A . H1N1 strains: A/WSN/1933, A/USSR/90/1977, A/Memphis/4/1987, A/Massachusetts/1/1990, A/Beijing/262/1995, A/New Caledonia/20/1999, A/Solomon Islands/3/2006, A/New York/08-1326/2008, A/California/07/2009, A/Michigan/45/2015, A/Sydney/5/2021. H3N2 strains: A/Aichi/2/1968, A/Bilthoven/1761/1976, A/Beijing/353/1989, A/Johannesburg/33/1994, A/Brisbane/8/1996, A/Fujian/411/2002, A/Wisconsin/67/2005, A/Perth/16/2009, A/Switzerland/9715293/2013, A/Kansas/14/2017. ( C ) ELISA binding reactivity at 10 or 1 µg/ml to A/Swine/Henan/SN13/2018 or A/Canine/Hainan/79/2019 (left) and BLI-based antibody competition with the indicated antibodies (right).
    Sino Biological Cat, supplied by Sino Biological, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/sino biological cat/product/Sino Biological
    Average 94 stars, based on 1 article reviews
    sino biological cat - by Bioz Stars, 2026-02
    94/100 stars
      Buy from Supplier

    91
    Sino Biological influenza a h1n1
    ( A ) Diversity of influenza A HA. Phylogenetic tree of influenza A virus HAs (left). Timeline of <t>influenza</t> <t>H1N1</t> and H3N2 circulation; symbols represent strains used in this study (middle). Pairwise identity of HAs from viruses used in this study mapped onto structures of HA (PDB: 3LZG and 4FNK) (right). ( B ) Neutralization potencies determined by microneutralization for down-selected antibodies against a panel of influenza A viruses. Strains are indicated as in A . H1N1 strains: A/WSN/1933, A/USSR/90/1977, A/Memphis/4/1987, A/Massachusetts/1/1990, A/Beijing/262/1995, A/New Caledonia/20/1999, A/Solomon Islands/3/2006, A/New York/08-1326/2008, A/California/07/2009, A/Michigan/45/2015, A/Sydney/5/2021. H3N2 strains: A/Aichi/2/1968, A/Bilthoven/1761/1976, A/Beijing/353/1989, A/Johannesburg/33/1994, A/Brisbane/8/1996, A/Fujian/411/2002, A/Wisconsin/67/2005, A/Perth/16/2009, A/Switzerland/9715293/2013, A/Kansas/14/2017. ( C ) ELISA binding reactivity at 10 or 1 µg/ml to A/Swine/Henan/SN13/2018 or A/Canine/Hainan/79/2019 (left) and BLI-based antibody competition with the indicated antibodies (right).
    Influenza A H1n1, supplied by Sino Biological, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/influenza a h1n1/product/Sino Biological
    Average 91 stars, based on 1 article reviews
    influenza a h1n1 - by Bioz Stars, 2026-02
    91/100 stars
      Buy from Supplier

    90
    Sino Biological influenza ah1n1
    ( A ) Diversity of influenza A HA. Phylogenetic tree of influenza A virus HAs (left). Timeline of <t>influenza</t> <t>H1N1</t> and H3N2 circulation; symbols represent strains used in this study (middle). Pairwise identity of HAs from viruses used in this study mapped onto structures of HA (PDB: 3LZG and 4FNK) (right). ( B ) Neutralization potencies determined by microneutralization for down-selected antibodies against a panel of influenza A viruses. Strains are indicated as in A . H1N1 strains: A/WSN/1933, A/USSR/90/1977, A/Memphis/4/1987, A/Massachusetts/1/1990, A/Beijing/262/1995, A/New Caledonia/20/1999, A/Solomon Islands/3/2006, A/New York/08-1326/2008, A/California/07/2009, A/Michigan/45/2015, A/Sydney/5/2021. H3N2 strains: A/Aichi/2/1968, A/Bilthoven/1761/1976, A/Beijing/353/1989, A/Johannesburg/33/1994, A/Brisbane/8/1996, A/Fujian/411/2002, A/Wisconsin/67/2005, A/Perth/16/2009, A/Switzerland/9715293/2013, A/Kansas/14/2017. ( C ) ELISA binding reactivity at 10 or 1 µg/ml to A/Swine/Henan/SN13/2018 or A/Canine/Hainan/79/2019 (left) and BLI-based antibody competition with the indicated antibodies (right).
    Influenza Ah1n1, supplied by Sino Biological, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/influenza ah1n1/product/Sino Biological
    Average 90 stars, based on 1 article reviews
    influenza ah1n1 - by Bioz Stars, 2026-02
    90/100 stars
      Buy from Supplier

    90
    Sino Biological caledonia 20 1999
    ( A ) Diversity of influenza A HA. Phylogenetic tree of influenza A virus HAs (left). Timeline of <t>influenza</t> <t>H1N1</t> and H3N2 circulation; symbols represent strains used in this study (middle). Pairwise identity of HAs from viruses used in this study mapped onto structures of HA (PDB: 3LZG and 4FNK) (right). ( B ) Neutralization potencies determined by microneutralization for down-selected antibodies against a panel of influenza A viruses. Strains are indicated as in A . H1N1 strains: A/WSN/1933, A/USSR/90/1977, A/Memphis/4/1987, A/Massachusetts/1/1990, A/Beijing/262/1995, A/New Caledonia/20/1999, A/Solomon Islands/3/2006, A/New York/08-1326/2008, A/California/07/2009, A/Michigan/45/2015, A/Sydney/5/2021. H3N2 strains: A/Aichi/2/1968, A/Bilthoven/1761/1976, A/Beijing/353/1989, A/Johannesburg/33/1994, A/Brisbane/8/1996, A/Fujian/411/2002, A/Wisconsin/67/2005, A/Perth/16/2009, A/Switzerland/9715293/2013, A/Kansas/14/2017. ( C ) ELISA binding reactivity at 10 or 1 µg/ml to A/Swine/Henan/SN13/2018 or A/Canine/Hainan/79/2019 (left) and BLI-based antibody competition with the indicated antibodies (right).
    Caledonia 20 1999, supplied by Sino Biological, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/caledonia 20 1999/product/Sino Biological
    Average 90 stars, based on 1 article reviews
    caledonia 20 1999 - by Bioz Stars, 2026-02
    90/100 stars
      Buy from Supplier

    Image Search Results


    ( A ) Diversity of influenza A HA. Phylogenetic tree of IAV HAs (left). Timeline of influenza H1N1 and H3N2 circulation; symbols represent strains used in this study (middle). Pairwise identity of HAs from viruses used in this study mapped onto structures of HA [Protein Data Bank (PDB) 3LZG and 4FNK] (right). ( B ) Neutralization potencies determined by microneutralization for down-selected antibodies against a panel of IAVs. Strains are indicated as in (A). H1N1 strains: A/WSN/1933, A/USSR/90/1977, A/Memphis/4/1987, A/Massachusetts/1/1990, A/Beijing/262/1995, A/New Caledonia/20/1999, A/Solomon Islands/3/2006, A/New York/08-1326/2008, A/California/07/2009, A/Michigan/45/2015, and A/Sydney/5/2021. H3N2 strains: A/Aichi/2/1968, A/Bilthoven/1761/1976, A/Beijing/353/1989, A/Johannesburg/33/1994, A/Brisbane/8/1996, A/Fujian/411/2002, A/Wisconsin/67/2005, A/Perth/16/2009, A/Switzerland/9715293/2013, and A/Kansas/14/2017. Neutralization assays were performed in technical duplicate. N.N., non-neutralizing. ( C ) ELISA binding reactivity at 10 or 1 μg/ml to A/Swine/Henan/SN13/2018 or A/Canine/Hainan/79/2019 (left) and BLI-based antibody competition with the indicated antibodies (right).

    Journal: Science Advances

    Article Title: Conserved sites on the influenza H1 and H3 hemagglutinin recognized by human antibodies

    doi: 10.1126/sciadv.adu9140

    Figure Lengend Snippet: ( A ) Diversity of influenza A HA. Phylogenetic tree of IAV HAs (left). Timeline of influenza H1N1 and H3N2 circulation; symbols represent strains used in this study (middle). Pairwise identity of HAs from viruses used in this study mapped onto structures of HA [Protein Data Bank (PDB) 3LZG and 4FNK] (right). ( B ) Neutralization potencies determined by microneutralization for down-selected antibodies against a panel of IAVs. Strains are indicated as in (A). H1N1 strains: A/WSN/1933, A/USSR/90/1977, A/Memphis/4/1987, A/Massachusetts/1/1990, A/Beijing/262/1995, A/New Caledonia/20/1999, A/Solomon Islands/3/2006, A/New York/08-1326/2008, A/California/07/2009, A/Michigan/45/2015, and A/Sydney/5/2021. H3N2 strains: A/Aichi/2/1968, A/Bilthoven/1761/1976, A/Beijing/353/1989, A/Johannesburg/33/1994, A/Brisbane/8/1996, A/Fujian/411/2002, A/Wisconsin/67/2005, A/Perth/16/2009, A/Switzerland/9715293/2013, and A/Kansas/14/2017. Neutralization assays were performed in technical duplicate. N.N., non-neutralizing. ( C ) ELISA binding reactivity at 10 or 1 μg/ml to A/Swine/Henan/SN13/2018 or A/Canine/Hainan/79/2019 (left) and BLI-based antibody competition with the indicated antibodies (right).

    Article Snippet: Briefly, His-tagged H1N1 A/California/04/2009 full-length trimer Y97F (Sino Biological, catalog no. 11055-V08B1) was mixed in 4:1 molar ratios with SA-allophycocyanin (APC; Invitrogen) and SA-phycoerythrin (PE; Invitrogen) whereas A/Darwin/6/2021 full-length soluble trimer and A/Hong Kong/1/1968 head trimer (see below) were mixed in 4:1 molar ratios with SA-PE (Invitrogen) and SA-APC (Invitrogen), respectively, and were incubated for 20 min on ice.

    Techniques: Neutralization, Enzyme-linked Immunosorbent Assay, Binding Assay

    Initial immune characterization of HA DNA-LNP formulations and immunogenicity (A) Schematic of DNA-LNP N/P ratios and immunization regimen. (B–D) Biophysical characterization of DNA-LNPs at different N/P ratios. (B) Particle size; (C) polydispersity index (PDI); (D) zeta potential. (E) Representative fluorescence-activated cell sorting (FACS) plots of GC B cells. (F) Bar plots quantifying frequency of GC B cells. (G) Frequency of CA09 HA-specific GC B cells. (H) Frequency of activated Tfh cells. (I) IFNγ ELISpot of splenocytes. (J) Representative TEM images of HA DNA-LNP (top) and HA mRNA-LNP (bottom). Scale bar 100 nm (K and L) Fold change cytokine induction in DLNs at 4 h (K) and 24 h (L) after immunization quantified using Luminex. (M and N) ELISpot assay measuring IFNα (M) and IFNγ (N) 20 h after stimulation of splenocytes ex vivo with DNA-LNP, plasmid DNA, or DNA-LNP in the presence of chemical inhibitors to the indicated DNA sensors. (O) Schematic of relevant pathways implicated in DNA-LNP sensing. Dots represent individual animals; n = 8–9 (E–H), n = 5 (I, K, and L), or n = 3–4 animals per group (L and M); data pooled or representative from two independent experiments (E–H, M, and N) or from one independent experiment (I–L). Plots show mean with SD (B–D and I) or geometric mean with geometric SD (F–H and K–N). Unpaired one-way ANOVA adjusted for multiple comparisons with Bonferroni corrections was used to compare groups (F–H, K, and L) or compared to DNA-LNP control (M and N). ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001.

    Journal: Cell Reports Medicine

    Article Title: Modulation of lipid nanoparticle-formulated plasmid DNA drives innate immune activation promoting adaptive immunity

    doi: 10.1016/j.xcrm.2025.102035

    Figure Lengend Snippet: Initial immune characterization of HA DNA-LNP formulations and immunogenicity (A) Schematic of DNA-LNP N/P ratios and immunization regimen. (B–D) Biophysical characterization of DNA-LNPs at different N/P ratios. (B) Particle size; (C) polydispersity index (PDI); (D) zeta potential. (E) Representative fluorescence-activated cell sorting (FACS) plots of GC B cells. (F) Bar plots quantifying frequency of GC B cells. (G) Frequency of CA09 HA-specific GC B cells. (H) Frequency of activated Tfh cells. (I) IFNγ ELISpot of splenocytes. (J) Representative TEM images of HA DNA-LNP (top) and HA mRNA-LNP (bottom). Scale bar 100 nm (K and L) Fold change cytokine induction in DLNs at 4 h (K) and 24 h (L) after immunization quantified using Luminex. (M and N) ELISpot assay measuring IFNα (M) and IFNγ (N) 20 h after stimulation of splenocytes ex vivo with DNA-LNP, plasmid DNA, or DNA-LNP in the presence of chemical inhibitors to the indicated DNA sensors. (O) Schematic of relevant pathways implicated in DNA-LNP sensing. Dots represent individual animals; n = 8–9 (E–H), n = 5 (I, K, and L), or n = 3–4 animals per group (L and M); data pooled or representative from two independent experiments (E–H, M, and N) or from one independent experiment (I–L). Plots show mean with SD (B–D and I) or geometric mean with geometric SD (F–H and K–N). Unpaired one-way ANOVA adjusted for multiple comparisons with Bonferroni corrections was used to compare groups (F–H, K, and L) or compared to DNA-LNP control (M and N). ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001.

    Article Snippet: B cell probes were generated via direct conjugation of fluorochromes to recombinant influenza virus CA09 HA (Cat# 11055-V08B1, Sino Biologicals).

    Techniques: Zeta Potential Analyzer, Fluorescence, FACS, Enzyme-linked Immunospot, Luminex, Ex Vivo, Plasmid Preparation, Control

    HA DNA-LNP induces robust GC and serum responses Mice were immunized with HA DNA-LNP (2 μg), HA mRNA-LNP (2 μg), or adjuvanted HA protein (1 μg). GC responses were assessed in the DLNs 14 days post immunization and serum responses longitudinally. (A) Representative FACS plots of activated Tfh cells. (B and C) Bar plots show quantification of frequency (B) and numbers (C) of activated Tfh cells. (D) Representative FACS plots of total GC B cells. (E and F) Bar plots show quantification of frequency (E) and numbers (F) of total GC B cells. (G) Representative FACS plots of CA09 HA-specific GC B cells. (H and I) Bar plots show frequency (H) and numbers (I) of CA09 HA-specific GC B cells. (J) Area under the curve (AUC) of total A/California/04/2009 HA-specific serum IgG ELISA data. (K) Serum endpoint titers at week 8 to various H1N1 HAs. (L) HAI titers at week 8 to A/California/07/2009 X-179A. (M and N) AUC of serum binding antibodies to A/Guangdong-Maonan/SWL1536/2019 HA (M) and A/Victoria/4897/2022 HA (N). (O and P) HAI titers to A/Netherlands/602/2009 (O) and A/New York City/PV63249/2022 (P). Dots represent individual animals (B, C, E, F, H, I, K, and L); n = 9–10 animals per group; data pooled from two independent experiments. Plots show geometric mean with geometric SD. Unpaired one-way ANOVA adjusted for multiple comparisons with Bonferroni corrections was used to compare groups (A–I) or active immunization groups (K). ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001.

    Journal: Cell Reports Medicine

    Article Title: Modulation of lipid nanoparticle-formulated plasmid DNA drives innate immune activation promoting adaptive immunity

    doi: 10.1016/j.xcrm.2025.102035

    Figure Lengend Snippet: HA DNA-LNP induces robust GC and serum responses Mice were immunized with HA DNA-LNP (2 μg), HA mRNA-LNP (2 μg), or adjuvanted HA protein (1 μg). GC responses were assessed in the DLNs 14 days post immunization and serum responses longitudinally. (A) Representative FACS plots of activated Tfh cells. (B and C) Bar plots show quantification of frequency (B) and numbers (C) of activated Tfh cells. (D) Representative FACS plots of total GC B cells. (E and F) Bar plots show quantification of frequency (E) and numbers (F) of total GC B cells. (G) Representative FACS plots of CA09 HA-specific GC B cells. (H and I) Bar plots show frequency (H) and numbers (I) of CA09 HA-specific GC B cells. (J) Area under the curve (AUC) of total A/California/04/2009 HA-specific serum IgG ELISA data. (K) Serum endpoint titers at week 8 to various H1N1 HAs. (L) HAI titers at week 8 to A/California/07/2009 X-179A. (M and N) AUC of serum binding antibodies to A/Guangdong-Maonan/SWL1536/2019 HA (M) and A/Victoria/4897/2022 HA (N). (O and P) HAI titers to A/Netherlands/602/2009 (O) and A/New York City/PV63249/2022 (P). Dots represent individual animals (B, C, E, F, H, I, K, and L); n = 9–10 animals per group; data pooled from two independent experiments. Plots show geometric mean with geometric SD. Unpaired one-way ANOVA adjusted for multiple comparisons with Bonferroni corrections was used to compare groups (A–I) or active immunization groups (K). ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001.

    Article Snippet: B cell probes were generated via direct conjugation of fluorochromes to recombinant influenza virus CA09 HA (Cat# 11055-V08B1, Sino Biologicals).

    Techniques: Enzyme-linked Immunosorbent Assay, Binding Assay

    HA DNA-LNP induces potent memory responses in mice and rabbits (A) Schematic of mouse immunization regimen. (B) IFNγ-secreting cells in splenocytes by ELISpot. (C) IFNγ-secreting effector CD8 + T cells by flow cytometry. (D) CA09 HA-specific ASC responses in bone marrow by ELISpot. (E) Representative FACS plot of CA09 HA-specific MBCs. (F and G) Bar plots show frequency (F) and numbers (G) of CA09 HA-specific MBCs. (H) Schematic of rabbit immunization regimen. (I–K) IFNγ ELISpot on peripheral blood mononuclear cells (PBMCs) at day 42 (I), day 105 (J), and day 202 (K). (L) AUC of total A/California/04/2009 HA-specific serum IgG ELISA data. (M and N) HAI titers to A/Netherlands/602/2009 (M) and A/New York City/PV63249/2022 (N). Dots represent individual animals (C, D, F, and G); n = 9–10 animals per group (B–D, F, and G), n = 5 animals per group (I–N); data pooled from two independent experiments. Plots show mean with SD (B and I–K) or geometric mean with geometric SD (C, D, F, G, and L–N). Unpaired one-way or two-way ANOVA adjusted for multiple comparisons with Bonferroni corrections was used to compare groups. ANOVA was performed at the final time point for (L–N). ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001.

    Journal: Cell Reports Medicine

    Article Title: Modulation of lipid nanoparticle-formulated plasmid DNA drives innate immune activation promoting adaptive immunity

    doi: 10.1016/j.xcrm.2025.102035

    Figure Lengend Snippet: HA DNA-LNP induces potent memory responses in mice and rabbits (A) Schematic of mouse immunization regimen. (B) IFNγ-secreting cells in splenocytes by ELISpot. (C) IFNγ-secreting effector CD8 + T cells by flow cytometry. (D) CA09 HA-specific ASC responses in bone marrow by ELISpot. (E) Representative FACS plot of CA09 HA-specific MBCs. (F and G) Bar plots show frequency (F) and numbers (G) of CA09 HA-specific MBCs. (H) Schematic of rabbit immunization regimen. (I–K) IFNγ ELISpot on peripheral blood mononuclear cells (PBMCs) at day 42 (I), day 105 (J), and day 202 (K). (L) AUC of total A/California/04/2009 HA-specific serum IgG ELISA data. (M and N) HAI titers to A/Netherlands/602/2009 (M) and A/New York City/PV63249/2022 (N). Dots represent individual animals (C, D, F, and G); n = 9–10 animals per group (B–D, F, and G), n = 5 animals per group (I–N); data pooled from two independent experiments. Plots show mean with SD (B and I–K) or geometric mean with geometric SD (C, D, F, G, and L–N). Unpaired one-way or two-way ANOVA adjusted for multiple comparisons with Bonferroni corrections was used to compare groups. ANOVA was performed at the final time point for (L–N). ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001.

    Article Snippet: B cell probes were generated via direct conjugation of fluorochromes to recombinant influenza virus CA09 HA (Cat# 11055-V08B1, Sino Biologicals).

    Techniques: Enzyme-linked Immunospot, Flow Cytometry, Enzyme-linked Immunosorbent Assay

    Journal: Cell Reports Medicine

    Article Title: Modulation of lipid nanoparticle-formulated plasmid DNA drives innate immune activation promoting adaptive immunity

    doi: 10.1016/j.xcrm.2025.102035

    Figure Lengend Snippet:

    Article Snippet: B cell probes were generated via direct conjugation of fluorochromes to recombinant influenza virus CA09 HA (Cat# 11055-V08B1, Sino Biologicals).

    Techniques: Virus, Recombinant, Lysis, Reporter Gene Assay, Cell Stimulation, Electron Microscopy, Luminex, Enzyme-linked Immunospot, Luciferase, Plasmid Preparation, Software, Synthesized

    ( A ) Diversity of influenza A HA. Phylogenetic tree of influenza A virus HAs (left). Timeline of influenza H1N1 and H3N2 circulation; symbols represent strains used in this study (middle). Pairwise identity of HAs from viruses used in this study mapped onto structures of HA (PDB: 3LZG and 4FNK) (right). ( B ) Neutralization potencies determined by microneutralization for down-selected antibodies against a panel of influenza A viruses. Strains are indicated as in A . H1N1 strains: A/WSN/1933, A/USSR/90/1977, A/Memphis/4/1987, A/Massachusetts/1/1990, A/Beijing/262/1995, A/New Caledonia/20/1999, A/Solomon Islands/3/2006, A/New York/08-1326/2008, A/California/07/2009, A/Michigan/45/2015, A/Sydney/5/2021. H3N2 strains: A/Aichi/2/1968, A/Bilthoven/1761/1976, A/Beijing/353/1989, A/Johannesburg/33/1994, A/Brisbane/8/1996, A/Fujian/411/2002, A/Wisconsin/67/2005, A/Perth/16/2009, A/Switzerland/9715293/2013, A/Kansas/14/2017. ( C ) ELISA binding reactivity at 10 or 1 µg/ml to A/Swine/Henan/SN13/2018 or A/Canine/Hainan/79/2019 (left) and BLI-based antibody competition with the indicated antibodies (right).

    Journal: bioRxiv

    Article Title: Conserved sites on the influenza H1 and H3 hemagglutinin recognized by human antibodies

    doi: 10.1101/2024.10.22.619298

    Figure Lengend Snippet: ( A ) Diversity of influenza A HA. Phylogenetic tree of influenza A virus HAs (left). Timeline of influenza H1N1 and H3N2 circulation; symbols represent strains used in this study (middle). Pairwise identity of HAs from viruses used in this study mapped onto structures of HA (PDB: 3LZG and 4FNK) (right). ( B ) Neutralization potencies determined by microneutralization for down-selected antibodies against a panel of influenza A viruses. Strains are indicated as in A . H1N1 strains: A/WSN/1933, A/USSR/90/1977, A/Memphis/4/1987, A/Massachusetts/1/1990, A/Beijing/262/1995, A/New Caledonia/20/1999, A/Solomon Islands/3/2006, A/New York/08-1326/2008, A/California/07/2009, A/Michigan/45/2015, A/Sydney/5/2021. H3N2 strains: A/Aichi/2/1968, A/Bilthoven/1761/1976, A/Beijing/353/1989, A/Johannesburg/33/1994, A/Brisbane/8/1996, A/Fujian/411/2002, A/Wisconsin/67/2005, A/Perth/16/2009, A/Switzerland/9715293/2013, A/Kansas/14/2017. ( C ) ELISA binding reactivity at 10 or 1 µg/ml to A/Swine/Henan/SN13/2018 or A/Canine/Hainan/79/2019 (left) and BLI-based antibody competition with the indicated antibodies (right).

    Article Snippet: Briefly, His-tagged H1N1 A/California/04/2009 full length trimer Y97F (Sino Biological Cat # 11055-V08B1) was mixed in 4:1 molar ratios with SA-Allophycocyanin (APC; Invitrogen) and SA phycoerythrin (PE; Invitrogen) while A/Darwin/6/2021 full-length soluble trimer and A/Hong Kong/1/1968 head trimer (see below) were mixed in 4:1 molar ratios with SA phycoerythrin (PE; Invitrogen) and SA-Allophycocyanin (APC; Invitrogen), respectively, and were incubated for 20 min on ice.

    Techniques: Virus, Neutralization, Enzyme-linked Immunosorbent Assay, Binding Assay